GlassScriptPhysician profile
Kenneth Newell
NPI 1447292529
$49,512.57
in general payments reported to CMS, 2019-2025
9 companies · $90.00 in 2025
The $90.00 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2021: $4,200 · 2022: $10K · 2023: $1,045 · 2024: $11K · 2025: $90.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Travel and Lodging: $1,045 · Food and Beverage: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,500.00 |
| Travel and Lodging | $1,045.29 |
| Food and Beverage | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $19,808.79 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $10,500.00 | 2024 | Uvadex |
| Mallinckrodt Enterprises LLC | $6,892.40 | 2019 | |
| Sanofi-Aventis U.S. LLC | $4,820.07 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $4,200.00 | 2021 | |
| Immucor, INC. | $1,900.00 | 2022 | |
| Merck Sharp & Dohme LLC | $1,045.29 | 2023 | |
| Veloxis Pharmaceuticals, INC. | $256.02 | 2019 | |
| Kamada LTD. | $90.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Newell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.